Led by $3.12bn private equity deal with Evident, Asia-Pacific’s medical devices industry saw a drop of 32.82% in cross border deal activity during Q3 2022, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

A total of 22 cross border deals worth $3.3bn were announced for the region during Q3 2022, against the last four-quarter average of 32.75 deals.

Of all the deal types, venture financing saw most activity in Q3 2022 with 17 deals, representing a 77.3% share for the region.

In second place was M&A with four deals, followed by private equity deals with one transactions, respectively capturing an 18.2% and 4.6% share of the overall cross border deal activity for the quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In terms of value of cross border deals, private equity was the leading category in Asia-Pacific’s medical devices industry with $3.12bn, followed by venture financing deals totalled $142.71m.

Asia-Pacific medical devices industry cross border deals in Q3 2022: Top deals

The top five medical devices cross border deals accounted for a 98.6% share of the overall value during Q3 2022.

The combined value of the top five cross border deals stood at $3.22bn, against the overall value of $3.3bn recorded for the quarter.

1) Bain Capital’s $3.12bn private equity deal with Evident

2) The $52.57m venture financing of CureApp by The Carlyle Group

3) Hillhouse Ventures and Proxima Ventures’s $14.8m venture financing deal with Shanghai Biohandler Life Sci-Tech

4) The $14.79m venture financing of Kolo Medical (Suzhou) by GAN Ventures and Walden International (China)

5) Meihong Investment, Powerfang Capital, Proxima Ventures and Taiyu Investment’s $14.37m venture financing deal with Beijing Leading Medical Valley Technology Development